Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage renal disease (ESRD) in young adults. However, current treatment options often yield suboptimal outcomes, highlighting the need for more effective therapies. This study aimed to evaluate the efficacy and safety of telitacicept, a novel dual-targeting biologic agent, in a real-world cohort of patients with IgA nephropathy.
In this retrospective study, 46 patients with biopsy-proven primary IgAN were included. All participants had baseline 24-hour proteinuria >0.5 g/day and an estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m². Patients were divided into two groups: the telitacicept group (n=23) received subcutaneous telitacicept (160 mg/week) plus oral prednisone (0.2-0.5 mg/kg/day), while the control group (n=23) received prednisone alone. Changes in proteinuria, measured by the urine albumin-to-creatinine ratio (UACR), and renal function (eGFR) were assessed at baseline, 4, 12, and 24 weeks. All adverse events (AEs) were systematically documented.
Continuous variables are presented as mean ± standard deviation or median (interquartile range) based on their distribution. Categorical variables are expressed as frequencies (percentages). Baseline characteristics between the two groups were compared using the Student's t-test or Mann-Whitney U test for continuous variables, and the Chi-square or Fisher's exact test for categorical variables, as appropriate. Changes in UACR and eGFR from baseline to each time point within groups were analyzed using paired t-tests or Wilcoxon signed-rank tests. Between-group comparisons of the percent reduction in UACR were performed using analysis of covariance (ANCOVA), adjusting for baseline values. A two-sided p-value < 0.05 was considered statistically significant. All analyses were conducted using SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA).
After 24 weeks of treatment, both groups showed significant reductions in UACR from baseline (p < 0.01). However, the reduction was significantly greater in the telitacicept group at all time points. At 4 weeks, the mean UACR reduction was 64.29% in the telitacicept group versus 47.43% in the control group (p < 0.05). This trend continued at 12 weeks (78.25% vs. 61.25%, p < 0.05) and 24 weeks (85.40% vs. 68.63%, p < 0.05). In contrast, there were no significant between-group differences in the change of eGFR from baseline at any time point (p > 0.05). No severe adverse events were reported in either group.
In this real-world study, the combination of telitacicept and conventional immunosuppressive therapy demonstrated superior efficacy in reducing proteinuria compared to immunosuppressive therapy alone, with a favorable safety profile. These findings suggest that telitacicept may represent a promising treatment strategy for delaying renal disease progression in IgAN.
